# Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

> **NCT05305924** · PHASE2 · RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 28 (estimated)

## Conditions studied

- ER-Positive Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Fulvestrant Run-In

## Key facts

- **NCT ID:** NCT05305924
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-25
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305924, "Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05305924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*